Geode Capital Management LLC Grows Stake in Metsera Inc. $MTSR

Geode Capital Management LLC raised its position in shares of Metsera Inc. (NASDAQ:MTSR) by 7.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 466,955 shares of the company’s stock after purchasing an additional 32,308 shares during the quarter. Geode Capital Management LLC owned 0.44% of Metsera worth $13,287,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Strs Ohio bought a new stake in shares of Metsera in the first quarter worth approximately $76,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Metsera in the second quarter worth $122,000. Corebridge Financial Inc. purchased a new stake in Metsera in the 1st quarter worth $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Metsera during the first quarter worth about $248,000. Finally, MetLife Investment Management LLC bought a new stake in shares of Metsera during the first quarter valued at approximately $254,000.

Metsera Price Performance

Shares of MTSR stock opened at $70.50 on Tuesday. Metsera Inc. has a 1 year low of $12.30 and a 1 year high of $83.86. The firm has a market capitalization of $7.42 billion and a price-to-earnings ratio of -11.16. The business has a fifty day moving average of $60.89 and a 200 day moving average of $42.81.

Metsera (NASDAQ:MTSR) last issued its earnings results on Wednesday, November 12th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.55).

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Leerink Partners reaffirmed a “market perform” rating and issued a $57.00 target price (down from $77.00) on shares of Metsera in a report on Wednesday, September 24th. Weiss Ratings reissued a “sell (d)” rating on shares of Metsera in a research report on Wednesday, October 8th. Leerink Partnrs lowered Metsera from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 24th. Wells Fargo & Company downgraded shares of Metsera from an “overweight” rating to an “equal weight” rating and set a $54.00 price target for the company. in a research note on Tuesday, September 30th. Finally, Bank of America lifted their price objective on Metsera from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 28th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $55.75.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.